Lytix Biopharma AS Asset Resilience Ratio

Latest as of December 2025: 88.76%

Lytix Biopharma AS asset resilience ratio. Lytix Biopharma AS (LYTIX) has an Asset Resilience Ratio of 88.76% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LYTIX defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Nkr72.36 Million
≈ $7.61 Million USD Cash + Short-term Investments

Total Assets

Nkr81.52 Million
≈ $8.58 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Lytix Biopharma AS (2017–2025)

Asset resilience ratio of Lytix Biopharma AS from 2017 to 2025. This chart shows how Lytix Biopharma AS's Asset Resilience Ratio has changed over time. Read Lytix Biopharma AS balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Lytix Biopharma AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Lytix Biopharma AS.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Nkr10.60 Million 13.0%
Short-term Investments Nkr61.76 Million 75.75%
Total Liquid Assets Nkr72.36 Million 88.76%

Asset Resilience Insights

  • Very High Liquidity: Lytix Biopharma AS maintains exceptional liquid asset reserves at 88.76% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Lytix Biopharma AS Industry Peers by Asset Resilience Ratio

Compare Lytix Biopharma AS's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
HLB Co. Ltd
KQ:028300
Biotechnology 3.29%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Shanghai Medicilon Inc
SHG:688202
Biotechnology 6.69%
Blue Jet Healthcare Limited
NSE:BLUEJET
Biotechnology 13.81%
Hangzhou Biotest Biotech Co Ltd
SHG:688767
Biotechnology 0.56%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.76%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

Lytix Biopharma AS Asset Resilience Ratio by Year (2017–2025)

Lytix Biopharma AS asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Lytix Biopharma AS.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 88.76% Nkr72.36 Million
≈ $7.61 Million
Nkr81.52 Million
≈ $8.58 Million
-0.50pp
2024-12-31 89.26% Nkr130.79 Million
≈ $13.76 Million
Nkr146.53 Million
≈ $15.42 Million
+10.12pp
2023-12-31 79.14% Nkr50.55 Million
≈ $5.32 Million
Nkr63.87 Million
≈ $6.72 Million
-16.35pp
2022-12-31 95.49% Nkr145.16 Million
≈ $15.27 Million
Nkr152.02 Million
≈ $16.00 Million
-1.71pp
2021-12-31 97.20% Nkr197.28 Million
≈ $20.76 Million
Nkr202.96 Million
≈ $21.36 Million
+9.98pp
2020-12-31 87.22% Nkr28.45 Million
≈ $2.99 Million
Nkr32.62 Million
≈ $3.43 Million
+13.83pp
2019-12-31 73.40% Nkr12.80 Million
≈ $1.35 Million
Nkr17.43 Million
≈ $1.83 Million
-10.85pp
2018-12-31 84.25% Nkr49.62 Million
≈ $5.22 Million
Nkr58.90 Million
≈ $6.20 Million
+10.01pp
2017-12-31 74.23% Nkr34.96 Million
≈ $3.68 Million
Nkr47.09 Million
≈ $4.96 Million
--
pp = percentage points

About Lytix Biopharma AS

OL:LYTIX Norway Biotechnology
Market Cap
$63.93 Million
Nkr607.51 Million NOK
Market Cap Rank
#20775 Global
#189 in Norway
Share Price
Nkr7.90
Change (1 day)
+2.07%
52-Week Range
Nkr7.50 - Nkr11.50
All Time High
Nkr18.60
About

Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic… Read more